LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

12.63 -2.7

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.58

Max

12.81

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+150.59% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-339M 1B
Vorige openingsprijs	15.33
Vorige sluitingsprijs	12.63

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 mei 2026, 23:46 UTC

Marktinformatie

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 mei 2026, 23:45 UTC

Marktinformatie

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 mei 2026, 23:42 UTC

Marktinformatie

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 mei 2026, 23:34 UTC

Marktinformatie

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 mei 2026, 23:11 UTC

Marktinformatie

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 mei 2026, 22:26 UTC

Acquisities, Fusies, Overnames

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 mei 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 mei 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 mei 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 mei 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 mei 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 mei 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 mei 2026, 22:11 UTC

Marktinformatie

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 mei 2026, 22:04 UTC

Marktinformatie

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 mei 2026, 08:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

23 mei 2026, 08:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

22 mei 2026, 21:10 UTC

Winsten

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

22 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 mei 2026, 19:47 UTC

Winsten

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mei 2026, 19:17 UTC

Marktinformatie

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mei 2026, 19:10 UTC

Marktinformatie

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 mei 2026, 18:54 UTC

Marktinformatie

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mei 2026, 18:38 UTC

Marktinformatie

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mei 2026, 18:35 UTC

Acquisities, Fusies, Overnames

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mei 2026, 18:09 UTC

Marktinformatie

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mei 2026, 17:58 UTC

Marktinformatie

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

150.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 150.59%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.